Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): Post-marketing surveillance in Japan

Modern Rheumatology

Volumn 28, Issue 1, 2018, Pages 48-57

  Takeuchi, Tsutomu ^a   Ishida, Kota ^b   Shiraki, Katsuhisa ^b   Yoshiyasu, Takashi ^b  

^a KEIO UNIVERSITY   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Add on therapy; biological DMARDs; post marketing surveillance; rheumatoid arthritis; tacrolimus

Indexed keywords

ABATACEPT; ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; STROMELYSIN; TACROLIMUS; TOCILIZUMAB; ANTIRHEUMATIC AGENT;

ADD ON THERAPY; ADULT; AGED; ARTICLE; DERMATOPHYTOSIS; DRUG EFFICACY; FEMALE; FEMORAL NECK FRACTURE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART FAILURE; HEART INFARCTION; HUMAN; JAPANESE (PEOPLE); KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MODIFIED HEALTH ASSESSMENT QUESTIONNAIRE; MUSCULOSKELETAL DISEASE ASSESSMENT; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT SAFETY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIMPLIFIED DISEASE ACTIVITY INDEX; SUBCUTANEOUS HEMORRHAGE; SWOLLEN JOINT COUNT; TAKOTSUBO CARDIOMYOPATHY; TENDER JOINT COUNT; TREATMENT RESPONSE; CLINICAL TRIAL; JAPAN; MIDDLE AGED;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; TACROLIMUS;

EID: 85021298380     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1080/14397595.2017.1332471     Document Type: Article

References (38)

1. McInnes IB, Schett G., The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–19.
2. O'Dell JR., Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004;350:2591–602.
3. Pavy S, Constantin A, Pham T, Gossec L, Maillefert JF, Cantagrel A, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73:388–95.
4. Visser K, van der Heijde DM., Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol. 2009;27:1017–25.
5. Salliot C, van der Heijde D., Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68:1100–4.
6. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68:1086–93.
7. Scott DL, Wolfe F, Huizinga TW., Rheumatoid arthritis. Lancet. 2010;376:1094–108.
8. Tugwell P, Singh JA, Wells GA., Biologicals for rheumatoid arthritis. BMJ. 2011;343:d4027.
9. Rubbert-Roth A, Finckh A., Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11(Suppl 1):S1.
10. Raychaudhuri S., Recent advances in the genetics of rheumatoid arthritis. Curr Opin Rheumatol. 2010;22:109–18.
11. Gizinski AM, Fox DA., T cell subsets and their role in the pathogenesis of rheumatic disease. Curr Opin Rheumatol. 2014;26:204–10.
12. Scott LJ, McKeage K, Keam SJ, Plosker GL., Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003;63:1247–97.
13. Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum. 2002;46:2020–8.
14. Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT, Borton MA, Tacrolimus Rheumatoid Arthritis Study Group, et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum. 2003;48:3328–37.
15. Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M, et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J Rheumatol. 2004;31:243–51.
16. Kawai S, Hashimoto H, Kondo H, Murayama T, Kiuchi T, Abe T., Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. J Rheumatol. 2006;33:2153–61.
17. Kawai S, Yamamoto K., Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatology (Oxford). 2006;45:441–4.
18. Takeuchi T, Kawai S, Yamamoto K, Harigai M, Ishida K, Miyasaka N., Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2014;24:8–16.
19. Naniwa T, Watanabe M, Banno S, Maeda T., Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies. Rheumatol Int. 2009;29:1287–91.
20. Miyata M, Asano T, Satoh S., Effect of additional administration of tacrolimus in patients with rheumatoid arthritis treated with biologics. Fukushima J Med Sci. 2011;57:54–9.
21. Mori S., Additional use of tacrolimus after switching to tocilizumab therapy in patients with primary lack of efficacy of infliximab therapy for rheumatoid arthritis. Mod Rheumatol. 2012;22:947–50.
22. Fujibayashi T, Takahashi N, Kida D, Kaneko A, Hirano Y, Fukaya N, et al. Comparison of efficacy and safety of tacrolimus and methotrexate in combination with abatacept in patients with rheumatoid arthritis; a retrospective observational study in the TBC Registry. Mod Rheumatol. 2015;25:825–30.
23. Takahashi N, Fujibayashi T, Kida D, Hirano Y, Kato T, Kato D, et al. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use. Rheumatol Int. 2015;35:1707–16.
24. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573–86.
25. Steinbrocker O, Traeger CH, Batterman RC., Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140:659–62.
26. van Rossum MA, Zwinderman AH, Boers M, Dijkmans BA, van Soesbergen RM, Fiselier TJ, et al. Radiologic features in juvenile idiopathic arthritis: a first step in the development of a standardized assessment method. Arthritis Rheum. 2003;48:507–15.
27. Gilliam BE, Chauhan AK, Low JM, Moore TL., Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. Clin Exp Rheumatol. 2008;26:492–7.
28. Yocum DE, Furst DE, Bensen WG, Burch FX, Borton MA, Mengle-Gaw LJ, et al. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (Oxford). 2004;43:992–9.
29. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42:244–57.
30. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis. 2007;66:1221–6.
31. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N., Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis. 2007;66:407–9.
32. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68:954–60.
33. Pincus T, Summey JA, Soraci SA, Jr, Wallston KA, Hummon NP., Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26:1346–53.
34. Posthumus MD, Limburg PC, Westra J, Cats HA, Stewart RE, van Leeuwen MA, et al. Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology (Oxford). 1999;38:1081–7.
35. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 2000;43:852–8.
36. Aletaha D, Smolen J., The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(Suppl 39):S100–S8.
37. ® Capsules (tacrolimus). Astellas Pharma Inc. [Japanese].
38. Ishida K, Shiraki K, Yoshiyasu T., Evaluation of the safety and effectiveness of add-on tacrolimus in patients with rheumatoid arthritis who failed to show an adequate response to biological DMARDs: the interim results of a specific drug use-results survey of tacrolimus. Drugs R D. 2015;15:307–17.